[vc_row][vc_column][vc_column_text][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=””]

Active psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis, characterized by joint pain, swelling, and stiffness. It commonly affects peripheral joints, entheses, and sometimes the spine. When termed “active,” it implies ongoing inflammation with clinical symptoms like tender or swollen joints, elevated inflammatory markers, or worsening skin lesions.

The Janus kinase (JAK) pathway plays a key role in PsA by mediating intracellular signaling of pro-inflammatory cytokines such as IL-23, IL-6, and interferons. Dysregulation in this pathway leads to overactivation of immune cells, promoting chronic inflammation and joint damage. JAK inhibitor Upadacitinib help by interrupting this signaling cascade.

[/vc_column_text][/vc_column][/vc_row][vc_row type=”vc_default” el_class=”box-sha”][vc_column width=”1/6″][/vc_column][vc_column width=”2/3″][vc_empty_space height=”20px”][vc_column_text css=”” el_class=”g-bg”]

Short Term Relief

[/vc_column_text][vc_empty_space height=”20px”][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text css=”” el_class=”title-bg”]

From week 2 many people started to see results

[/vc_column_text][vc_single_image image=”458″ img_size=”full” alignment=”center” css=””][/vc_column_inner][vc_column_inner width=”1/2″][vc_column_text css=”” el_class=”title-bg”]

From week 2 many people started
to see results 12 weeks

[/vc_column_text][vc_single_image image=”459″ img_size=”full” alignment=”center” css=””][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/6″][/vc_column][vc_column][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row type=”vc_default” el_class=”box-sha”][vc_column width=”1/6″][/vc_column][vc_column width=”2/3″][vc_column_text css=”” el_class=”g-bg”]

Long Term Relief

[/vc_column_text][vc_empty_space height=”20px”][vc_row_inner][vc_column_inner][vc_column_text css=”” el_class=”title-bg”]

Majority people continued taking Upadacitinib
saw improvement in PsA symptoms even at 3 years

[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”5/6″][vc_single_image image=”480″ img_size=”full” alignment=”center” css=””][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/6″][/vc_column][vc_column][vc_empty_space height=”60px”][/vc_column][/vc_row]